Published in Genome Med on April 07, 2010
Improving Autism Screening With Brain-Related miRNA | NCT02712853
MicroRNAs in neuronal function and dysfunction. Trends Neurosci (2012) 1.94
The continuing value of twin studies in the omics era. Nat Rev Genet (2012) 1.88
Aberrant expression of long noncoding RNAs in autistic brain. J Mol Neurosci (2012) 1.30
Functions of noncoding RNAs in neural development and neurological diseases. Mol Neurobiol (2011) 1.27
The Emerging Role of microRNAs in Schizophrenia and Autism Spectrum Disorders. Front Psychiatry (2012) 1.22
Characteristics and predictive value of blood transcriptome signature in males with autism spectrum disorders. PLoS One (2012) 1.09
Serum microRNA profiles in children with autism. Mol Autism (2014) 1.08
PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis. Childs Nerv Syst (2017) 1.05
MicroRNAs: Meta-controllers of gene expression in synaptic activity emerge as genetic and diagnostic markers of human disease. Pharmacol Ther (2011) 1.03
MicroRNA dysregulation in neuropsychiatric disorders and cognitive dysfunction. Neurobiol Dis (2012) 1.02
Biomarkers in autism spectrum disorder: the old and the new. Psychopharmacology (Berl) (2013) 1.01
A direct molecular link between the autism candidate gene RORa and the schizophrenia candidate MIR137. Sci Rep (2014) 1.00
Connecting the CNTNAP2 Networks with Neurodevelopmental Disorders. Mol Syndromol (2015) 1.00
The Path to microRNA Therapeutics in Psychiatric and Neurodegenerative Disorders. Front Genet (2012) 0.98
The enteric bacterial metabolite propionic acid alters brain and plasma phospholipid molecular species: further development of a rodent model of autism spectrum disorders. J Neuroinflammation (2012) 0.98
Insights on the functional impact of microRNAs present in autism-associated copy number variants. PLoS One (2013) 0.97
Genome-wide approaches in the study of microRNA biology. Wiley Interdiscip Rev Syst Biol Med (2010) 0.95
The Role of Epigenetic Change in Autism Spectrum Disorders. Front Neurol (2015) 0.95
Mood stabilizer-regulated miRNAs in neuropsychiatric and neurodegenerative diseases: identifying associations and functions. Am J Transl Res (2013) 0.92
Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut (2015) 0.88
Chronic academic stress increases a group of microRNAs in peripheral blood. PLoS One (2013) 0.87
MicroRNAs: Key Regulators in the Central Nervous System and Their Implication in Neurological Diseases. Int J Mol Sci (2016) 0.87
An eQTL mapping approach reveals that rare variants in the SEMA5A regulatory network impact autism risk. Hum Mol Genet (2013) 0.87
Systems Biology Reveals MicroRNA-Mediated Gene Regulation. Front Genet (2011) 0.86
AKAPs integrate genetic findings for autism spectrum disorders. Transl Psychiatry (2013) 0.85
Maturation of the human dorsolateral prefrontal cortex coincides with a dynamic shift in microRNA expression. Schizophr Bull (2013) 0.84
Mining the 3'UTR of autism-implicated genes for SNPs perturbing microRNA regulation. Genomics Proteomics Bioinformatics (2014) 0.83
The effect of freeze-thaw cycles on gene expression levels in lymphoblastoid cell lines. PLoS One (2014) 0.82
iPSC-derived neurons as a higher-throughput readout for autism: promises and pitfalls. Trends Mol Med (2013) 0.82
E Proteins and ID Proteins: Helix-Loop-Helix Partners in Development and Disease. Dev Cell (2015) 0.81
From genes to environment: using integrative genomics to build a "systems-level" understanding of autism spectrum disorders. Child Dev (2012) 0.81
Genetic variants of neurotransmitter-related genes and miRNAs in Egyptian autistic patients. ScientificWorldJournal (2013) 0.80
The TLX-miR-219 cascade regulates neural stem cell proliferation in neurodevelopment and schizophrenia iPSC model. Nat Commun (2016) 0.80
Specific Regional and Age-Related Small Noncoding RNA Expression Patterns Within Superior Temporal Gyrus of Typical Human Brains Are Less Distinct in Autism Brains. J Child Neurol (2015) 0.80
Profiling olfactory stem cells from living patients identifies miRNAs relevant for autism pathophysiology. Mol Autism (2016) 0.80
Investigation of Gene Regulatory Networks Associated with Autism Spectrum Disorder Based on MiRNA Expression in China. PLoS One (2015) 0.79
Assessing the impact of copy number variants on miRNA genes in autism by Monte Carlo simulation. PLoS One (2014) 0.79
Salivary miRNA profiles identify children with autism spectrum disorder, correlate with adaptive behavior, and implicate ASD candidate genes involved in neurodevelopment. BMC Pediatr (2016) 0.78
Horizons of psychiatric genetics and epigenetics: where are we and where are we heading? Iran J Psychiatry Behav Sci (2014) 0.78
Integrated analyses to reconstruct microRNA-mediated regulatory networks in mouse liver using high-throughput profiling. BMC Genomics (2015) 0.78
The expanding genomic landscape of autism: discovering the 'forest' beyond the 'trees' Future Neurol (2013) 0.77
Common microRNAs Target Established ASD Genes. Front Neurol (2014) 0.76
Functional genomics of human brain development and implications for autism spectrum disorders. Transl Psychiatry (2015) 0.76
Turing Revisited: Decoding the microRNA Messages in Brain Extracellular Vesicles for Early Detection of Neurodevelopmental Disorders. Curr Environ Health Rep (2016) 0.75
MicroRNAs of the miR379-410 cluster: New players in embryonic neurogenesis and regulators of neuronal function. Neurogenesis (Austin) (2015) 0.75
A Comparative Review of microRNA Expression Patterns in Autism Spectrum Disorder. Front Psychiatry (2016) 0.75
Microribonucleic acid dysregulations in children and adolescents with obsessive-compulsive disorder. Neuropsychiatr Dis Treat (2015) 0.75
Knowledge-Guided Bioinformatics Model for Identifying Autism Spectrum Disorder Diagnostic MicroRNA Biomarkers. Sci Rep (2016) 0.75
Phenotyping, Etiological Factors, and Biomarkers: Toward Precision Medicine in Autism Spectrum Disorders. J Dev Behav Pediatr (2016) 0.75
Fluoxetine Increases the Expression of miR-572 and miR-663a in Human Neuroblastoma Cell Lines. PLoS One (2016) 0.75
Comparison of blood RNA isolation methods from samples stabilized in Tempus tubes and stored at a large human biobank. BMC Res Notes (2016) 0.75
MIR137 is the key gene mediator of the syndromic obesity phenotype of patients with 1p21.3 microdeletions. Mol Cytogenet (2016) 0.75
The Role of MicroRNAs in Cerebellar Development and Autism Spectrum Disorder During Embryogenesis. Mol Neurobiol (2016) 0.75
Contribution of Inhibitor of DNA Binding/Differentiation-3 and Endocrine Disrupting Chemicals to Pathophysiological Aspects of Chronic Disease. Biomed Res Int (2017) 0.75
Bio-collections in autism research. Mol Autism (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
The functions of animal microRNAs. Nature (2004) 64.85
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res (2006) 39.25
TM4: a free, open-source system for microarray data management and analysis. Biotechniques (2003) 38.02
Most mammalian mRNAs are conserved targets of microRNAs. Genome Res (2008) 37.16
Human MicroRNA targets. PLoS Biol (2004) 34.51
Principles of microRNA-target recognition. PLoS Biol (2005) 23.70
Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med (2008) 19.71
miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev (2002) 19.24
MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol (2005) 18.94
Fast and effective prediction of microRNA/target duplexes. RNA (2004) 18.10
Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet (2003) 15.31
Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol (2004) 15.15
Microarray data normalization and transformation. Nat Genet (2002) 15.04
Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet (2006) 11.14
Ribo-gnome: the big world of small RNAs. Science (2005) 10.10
A microRNA array reveals extensive regulation of microRNAs during brain development. RNA (2003) 9.76
Transcription and processing of human microRNA precursors. Mol Cell (2004) 8.98
A MicroRNA feedback circuit in midbrain dopamine neurons. Science (2007) 8.33
Characterization of microRNA expression profiles in normal human tissues. BMC Genomics (2007) 8.01
Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet (2008) 7.13
Behavioral manifestations of autism in the first year of life. Int J Dev Neurosci (2005) 6.56
Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev (2002) 6.43
A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev (2002) 6.10
Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol (2005) 5.95
Transplanted suprachiasmatic nucleus determines circadian period. Science (1990) 5.55
Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders. Am J Hum Genet (2008) 5.44
A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. Am J Hum Genet (2008) 5.28
Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet (2008) 5.04
The postsynaptic architecture of excitatory synapses: a more quantitative view. Annu Rev Biochem (2007) 4.75
Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. Brain Res (1972) 4.58
microRNA modulation of circadian-clock period and entrainment. Neuron (2007) 4.49
Cerebellar neurodegeneration in the absence of microRNAs. J Exp Med (2007) 4.48
Magnetic resonance imaging and head circumference study of brain size in autism: birth through age 2 years. Arch Gen Psychiatry (2005) 3.94
Genome-wide scan for autism susceptibility genes. Paris Autism Research International Sibpair Study. Hum Mol Genet (1999) 3.93
Open source software for the analysis of microarray data. Biotechniques (2003) 3.89
A genomewide screen for autism: strong evidence for linkage to chromosomes 2q, 7q, and 16p. Am J Hum Genet (2001) 3.54
A synaptic trek to autism. Curr Opin Neurobiol (2009) 3.53
Analysis of strain and regional variation in gene expression in mouse brain. Genome Biol (2001) 3.43
Collagen VI related muscle disorders. J Med Genet (2005) 3.38
Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci (1999) 3.16
MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biol (2007) 3.05
Autism and pervasive developmental disorders. J Child Psychol Psychiatry (2004) 2.96
Gastrointestinal abnormalities in children with autistic disorder. J Pediatr (1999) 2.96
When is the brain enlarged in autism? A meta-analysis of all brain size reports. Biol Psychiatry (2005) 2.94
A genomewide screen for autism-spectrum disorders: evidence for a major susceptibility locus on chromosome 3q25-27. Am J Hum Genet (2002) 2.74
Targeted protein degradation and synapse remodeling by an inducible protein kinase. Science (2003) 2.63
RNA and microRNAs in fragile X mental retardation. Nat Cell Biol (2004) 2.63
Polo-like kinases: a team in control of the division. Cell Cycle (2006) 2.62
Predicting and validating microRNA targets. Genome Biol (2004) 2.54
Microcephaly and macrocephaly in autism. J Autism Dev Disord (1999) 2.54
Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab (2007) 2.52
A genomewide screen of 345 families for autism-susceptibility loci. Am J Hum Genet (2003) 2.51
Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics (2008) 2.50
Autism profiles of males with fragile X syndrome. Am J Ment Retard (2008) 2.35
Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity. Neuron (2008) 2.29
Macrocephaly in children and adults with autism. J Am Acad Child Adolesc Psychiatry (1997) 2.26
Molecular genetics of human microcephaly. Curr Opin Neurol (2001) 2.25
MicroRNA target prediction by expression analysis of host genes. Genome Res (2008) 2.21
Ratio statistics of gene expression levels and applications to microarray data analysis. Bioinformatics (2002) 2.19
Localized enlargement of the frontal cortex in early autism. Biol Psychiatry (2005) 2.15
Neuropathology of infantile autism. J Neuropathol Exp Neurol (1998) 2.04
MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci U S A (2009) 2.00
Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem (2000) 1.97
A miRNA signature of prion induced neurodegeneration. PLoS One (2008) 1.96
An MRI study of brain size in autism. Am J Psychiatry (1995) 1.92
Non-coding RNAs in the nervous system. J Physiol (2006) 1.87
Prevalence of motor impairment in autism spectrum disorders. Brain Dev (2007) 1.80
Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry (2007) 1.79
Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism. J Autism Dev Disord (2001) 1.77
The polo-like protein kinases Fnk and Snk associate with a Ca(2+)- and integrin-binding protein and are regulated dynamically with synaptic plasticity. EMBO J (1999) 1.75
Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr (2006) 1.74
Gene expression profiling of lymphoblastoid cell lines from monozygotic twins discordant in severity of autism reveals differential regulation of neurologically relevant genes. BMC Genomics (2006) 1.73
Development of a mouse test for repetitive, restricted behaviors: relevance to autism. Behav Brain Res (2007) 1.71
A role for Id2 in regulating photic entrainment of the mammalian circadian system. Curr Biol (2009) 1.70
Regional brain enlargement in autism: a magnetic resonance imaging study. J Am Acad Child Adolesc Psychiatry (1996) 1.70
Further characterization of the autism susceptibility locus AUTS1 on chromosome 7q. Hum Mol Genet (2001) 1.69
The Drosophila homeotic target gene centrosomin (cnn) encodes a novel centrosomal protein with leucine zippers and maps to a genomic region required for midgut morphogenesis. Development (1995) 1.69
Advances in behavioral genetics: mouse models of autism. Mol Psychiatry (2007) 1.68
Brain overgrowth in autism during a critical time in development: implications for frontal pyramidal neuron and interneuron development and connectivity. Int J Dev Neurosci (2005) 1.65
Amygdala enlargement in toddlers with autism related to severity of social and communication impairments. Biol Psychiatry (2009) 1.63
The role of GW/P-bodies in RNA processing and silencing. J Cell Sci (2007) 1.63
Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr (2005) 1.62
The neuroligin and neurexin families: from structure to function at the synapse. Cell Mol Life Sci (2006) 1.59
Autism in infancy and early childhood. Annu Rev Psychol (2005) 1.59
Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology (2007) 1.56
Novel splice isoforms for NLGN3 and NLGN4 with possible implications in autism. J Med Genet (2006) 1.54
Gene expression profiling differentiates autism case-controls and phenotypic variants of autism spectrum disorders: evidence for circadian rhythm dysfunction in severe autism. Autism Res (2009) 1.53
Dominant collagen VI mutations are a common cause of Ullrich congenital muscular dystrophy. Hum Mol Genet (2004) 1.51
Cortical gray and white brain tissue volume in adolescents and adults with autism. Biol Psychiatry (2005) 1.50
Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures. Nat Genet (1996) 1.47
Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology (2005) 1.47
The possible interplay of synaptic and clock genes in autism spectrum disorders. Cold Spring Harb Symp Quant Biol (2007) 1.45
Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid. Proc Natl Acad Sci U S A (2007) 1.45
Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry (2001) 1.44
Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci (2005) 1.44
Genome-wide and Ordered-Subset linkage analyses provide support for autism loci on 17q and 19p with evidence of phenotypic and interlocus genetic correlates. BMC Med Genet (2005) 1.44
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Group SCAD regression analysis for microarray time course gene expression data. Bioinformatics (2007) 3.04
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Defining the mammalian CArGome. Genome Res (2005) 2.59
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17
Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE (2004) 2.04
Expansion of adult beta-cell mass in response to increased metabolic demand is dependent on HNF-4alpha. Genes Dev (2007) 1.97
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci (2012) 1.80
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79
Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology (2008) 1.79
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74
An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Information filtering via a scaling-based function. PLoS One (2013) 1.56
The Wnt signaling pathway in bipolar disorder. Neuroscientist (2002) 1.53
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51
Monoamine oxidase A gene polymorphism predicts adolescent outcome of attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2007) 1.51
Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci (2004) 1.45
Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology (2007) 1.42
Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2007) 1.41
Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology (2008) 1.41
In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology (2004) 1.41
[Possible involvement of protein kinase C in the pathophysiology and treatment of bipolar disorder]. Harefuah (2004) 1.40
Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry (2007) 1.40
Sex hormones in autism: androgens and estrogens differentially and reciprocally regulate RORA, a novel candidate gene for autism. PLoS One (2011) 1.40
Molecular effects of lithium. Mol Interv (2004) 1.39
Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum (2008) 1.38
Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A (2009) 1.38
A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry (2009) 1.33
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. Biol Psychiatry (2010) 1.32
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry (2004) 1.29
Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2008) 1.29
The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biol Psychiatry (2009) 1.29
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol (2009) 1.28
Endophenotypes in bipolar disorder. Am J Med Genet (2002) 1.25
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc Natl Acad Sci U S A (2008) 1.25
Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology (2006) 1.24
Bipolar disorder: from genes to behavior pathways. J Clin Invest (2009) 1.24
Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics (2010) 1.23
Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry (2006) 1.23
Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets (2006) 1.23
Suppression of adult neurogenesis leads to an increased hypothalamo-pituitary-adrenal axis response. Neuroreport (2009) 1.23
Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry (2013) 1.21
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci (2008) 1.19
Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol (2006) 1.16
Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. Neuroimage (2009) 1.16
Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology (2007) 1.16
Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol (2005) 1.15
Innovative approach to the design of low-cost Zr-based BMG composites with good glass formation. Sci Rep (2013) 1.14
Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology (2003) 1.13
Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry (2006) 1.13
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13
Regional cerebral glucose metabolic abnormalities in bipolar II depression. Biol Psychiatry (2006) 1.13
Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry (2006) 1.12
G protein-coupled receptors in major psychiatric disorders. Biochim Biophys Acta (2006) 1.12
Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci (2003) 1.11
A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A (2010) 1.11
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol (2012) 1.11
Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism. Invest Ophthalmol Vis Sci (2003) 1.11
Generation and behavioral characterization of beta-catenin forebrain-specific conditional knock-out mice. Behav Brain Res (2008) 1.10
The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci (2005) 1.10
In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry (2007) 1.10
MicroRNAs in mental health: from biological underpinnings to potential therapies. Neuromolecular Med (2009) 1.09